New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B.
10.4166/kjg.2011.57.3.144
- Author:
Yoo Kyung CHO
1
;
Byung Cheol SONG
Author Information
1. Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. drsong@jejunu.ac.kr
- Publication Type:Review ; English Abstract
- Keywords:
Chronic hepatitis B;
Hepatitis B virus DNA;
Hepatitis B surface antigens
- MeSH:
Antiviral Agents/*therapeutic use;
Carcinoma, Hepatocellular/etiology;
DNA, Viral/*blood;
Hepatitis B Surface Antigens/*blood;
Hepatitis B virus/*genetics;
Hepatitis B, Chronic/complications/*drug therapy;
Humans;
Lamivudine/therapeutic use;
Liver Cirrhosis/etiology;
Liver Neoplasms/etiology;
Nucleosides/therapeutic use;
Pyrimidinones/therapeutic use
- From:The Korean Journal of Gastroenterology
2011;57(3):144-149
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Over the past decade, advances in the antiviral therapy in patients with chronic hepatitis B have enabled the sustained suppression of hepatitis B viral replication and the prevention of progressive liver disease. Hepatitis B surface antigen (HBsAg) has been used to diagnose patients with hepatitis B virus infection. Recently, test for quantitative HBsAg titers are available and on-treatment HBsAg quantitations are used to predict treatment outcome. Serum HBV DNA levels have been shown to predict natural course of chronic hepatitis B infection. The HBV DNA levels have been reported to be positively correlated with the development of cirrhosis, hepatocellular carcinoma and related death. The baseline and on-treatment levels of HBV DNA are important factors for predicting treatment outcomes. In this article, we will discuss the role of HBV DNA and HBsAg quantitation during antiviral therapy.
